As regards ``projected revenues driving the market``:

I would agree with you only IF support of the share price were to depend on existing shareholders and those who have followed this company for years. It is generally accepted that most of us are either in the long camp with very little money left to spend, or in the angry/show me camp. However, I believe this is a very narrow perspective and the couple of hundred existing and former shareholders will be pushed aside by new investors interested in the ``bio-tech`` market. I expect that there are already ``buyers`` waiting in the wings to hear the JV is a done deal. They will want to get in on the ground floor.

I also suspect that if it is possible for announcements to be made of purchase orders received, or production output, there will be new investors that will move on this information, and not be quite as reluctant as the handful of Longs, former longs, and those in between, who may want to ``wait and see``.

Best regards,

-z